Matisse Capital decreased its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 73.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,100 shares of the company's stock after selling 70,617 shares during the quarter. Matisse Capital's holdings in Fulcrum Therapeutics were worth $180,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Exome Asset Management LLC grew its stake in Fulcrum Therapeutics by 143.0% in the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock valued at $1,985,000 after acquiring an additional 405,538 shares during the period. Acadian Asset Management LLC grew its stake in Fulcrum Therapeutics by 865.0% in the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock valued at $989,000 after acquiring an additional 308,854 shares during the period. ADAR1 Capital Management LLC grew its stake in Fulcrum Therapeutics by 150.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 490,532 shares of the company's stock valued at $1,413,000 after acquiring an additional 294,284 shares during the period. Nuveen LLC acquired a new stake in Fulcrum Therapeutics in the 1st quarter valued at $441,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Fulcrum Therapeutics in the 1st quarter valued at $425,000. Institutional investors and hedge funds own 89.83% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on FULC. Royal Bank Of Canada lifted their target price on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a research note on Wednesday, July 30th. HC Wainwright upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $4.00 to $12.00 in a report on Tuesday, July 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Fulcrum Therapeutics in a report on Saturday, September 27th. Finally, Wall Street Zen raised shares of Fulcrum Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.60.
Check Out Our Latest Stock Analysis on Fulcrum Therapeutics
Fulcrum Therapeutics Stock Down 2.7%
Shares of Fulcrum Therapeutics stock opened at $9.24 on Wednesday. The firm has a market capitalization of $499.79 million, a P/E ratio of -7.57 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $9.70. The firm's 50 day moving average is $7.29 and its two-hundred day moving average is $6.21.
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. As a group, research analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.
About Fulcrum Therapeutics
(
Free Report)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Further Reading
Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fulcrum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.
While Fulcrum Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
